
Share
Choosing Polymeric Delivery for Advanced Therapeutics
Polymeric nanoparticles (PNPs) and polymeric microspheres (PMPs) offer many benefits for delivering active pharmaceutical ingredients (APIs), including small molecules, peptides, proteins, and nucleic acids. Selecting the right platform depends on the API's properties, the desired release profile, and the specific delivery challenges to address. Understanding these differences can help developers determine whether a PNP or PMP fits a particular drug development program.
Benefits of Formulating Advanced Therapeutics as Polymeric Nanoparticles and Microspheres

Why Polymeric Delivery?
Polymeric systems can improve patient convenience and compliance, enhance tolerability, capture new IP space, and provide an alternative intercellular delivery strategy.
PNPs and PMPs offer different advantages within this broader range of applications. Compared with lipid nanoparticles (LNPs), PNPs can offer extended half-lives because they do not exhibit the same burst-release profile commonly associated with liposomes or LNPs. The major benefit of PMPs, meanwhile, is their potential to provide long-acting release.
These benefits are not merely theoretical. Polymeric delivery systems have already been proven in commercial sustained-release products. ZILRETTA® (Pacira Biosciences), used to treat osteoarthritis knee pain, is formulated with biodegradable poly(lactic-co-glycolic acid) (PLGA) microparticles and is widely considered a gold standard in the field.
PNPs and Microspheres: What’s the Difference?
PNPs and PMPs are typically distinguished by their size. In line with FDA guidance, Phosphorex considers PNPs to have diameters <500 nm, while PMPs are larger. Why does this distinction matter? PNPs can support intercellular delivery strategies, while microspheres cannot. Particle size can also directly affect manufacturability. One clear example is filtration. Because of their small size, PNPs can typically be filtered through 0.2-micron sterilizing filters before fill-and-finish. PMPs, however, may require terminal sterilization or fully aseptic processing within a controlled sterile environment, depending on the cargo.
A Developer’s Guide to Selection, Manufacturing and Analysis
Novel delivery systems may perform well at the benchtop but encounter significant challenges when the technology is transferred to scalable, clinically relevant manufacturing processes. For developers considering polymeric delivery systems, it is important to consider all aspects of development from the outset, including API compatibility, polymer selection, targeted-delivery methods, manufacturability, and stage-appropriate analytical methods. Considering these factors early can help identify potential development challenges before selecting candidates and reduce the risk of redesign as programs advance.
API Compatibility
Small molecules, peptides, proteins, and nucleic acids do not behave the same way. A delivery system must therefore be designed around the API's properties and the intended delivery route. These factors can help guide the choice between PNPs and PMPs, as both platforms can accommodate a wide range of API formats but offer different strengths.
Polymer Chemistry
The materials used to produce polymeric delivery systems consist primarily of biocompatible polymers containing hydrolyzable esters for biodegradation. Fine-tuning these polymer structures can improve drug loading, drug release, and manufacturability to meet the target product profile. Importantly, different particles may carry the same API but behave very differently depending on the polymer used to make them.
PMPs can be produced using a range of biodegradable polymers, including PLGA and PLA, as well as polycaprolactone (PCL), polyanhydrides, and poly(ortho esters). For encapsulating small molecules and peptides, PLGA- and polylactic acid (PLA)-derived polymers are generally preferred because they balance API loading, tunable release rates, and manufacturability. This performance can be tuned by adjusting the polymer molecular weight (MW) and/or the lactide-to-glycolide (LA/GA) ratio.
In contrast, polymers used in PNP formulations are often modified with polyethylene glycol (PEG), which can support the formation of smaller particles and provide sites for attaching surface ligands, such as antibodies and other molecules that support active targeted delivery.
Targeted Delivery Through Surface Modification
The ability to modify PNP surfaces enables targeted delivery approaches beyond those available with lipid- based systems. Their extended half-life can also increase exposure to target tissues and support target uptake. With active targeting, ligands such as antibody fragments, nanobodies, peptides, and small molecules can be chemically conjugated to the surfaces of drug-loaded PNPs.
Conjugation can typically be achieved using approaches such as maleimide bioconjugation or copper-free click chemistry. Fluorescent dyes and imaging agents can also be conjugated to or encapsulated within PNPs for in vivo imaging applications.
Stage-Appropriate Analysis
PNPs and PMPs are complex delivery systems, making intentional, well-structured experiments important from the outset of development. Stage-appropriate analytical methods can provide the data needed to characterize discovery prototypes, compare formulations, and identify potential manufacturability challenges before nominating candidates.
Powerful analytical methods, including high-performance liquid chromatography (HPLC), can provide more detailed characterization of discovery prototypes than simpler plate-based methods, supporting better- informed candidate selection. Identifying manufacturability and product-quality challenges early can allow selected candidates to move through development without significant redesign or repeated development work.
Taken together, API compatibility, polymer chemistry, targeted delivery, manufacturability, and stage- appropriate analysis provide a framework for selecting and advancing polymeric delivery systems from early development through clinical manufacturing.
Enabling Delivery for Advanced Therapeutics
Phosphorex has focused on polymeric delivery systems since its founding more than 20 years ago. With expertise in PNP and PMP development, Phosphorex helps developers evaluate delivery options based on API properties, desired release profiles, manufacturability, and development goals. By considering scalability, reproducibility, and regulatory expectations from the outset, Phosphorex helps partners de-risk the development path from platform selection through IND filing.
Contact us to discuss the right polymeric delivery approach for your project.